Literature DB >> 16860269

Gender differences in depression and response to psychotropic medication.

Jack M Gorman1.   

Abstract

BACKGROUND: In the United States, depression is approximately twice as common among women as among men, across all age groups.
OBJECTIVE: This review examines gender differences in the epidemiology and clinical presentation of depression, and explores whether women respond differently than men to antidepressant medications.
METHODS: This is a selective review focusing on current issues in the management of depression, with particular attention to gender differences in the epidemiology, diagnosis, and treatment of the disease.
RESULTS: Women are more likely than men to have atypical symptoms of depression (eg, hypersomnia, hyperphagia), to have comorbid anxiety disorders, and to attempt suicide. Women are also more likely to have seasonal affective disorder. Mood and anxiety symptoms that seem to be related to the menstrual cycle do not often represent genuine premenstrual dysphoria, but when premenstrual dysphoric disorder does occur, its impact on quality of life is similar to that of major depressive disorder. There is ongoing controversy about whether men and women respond equally well to antidepressant medications, and preliminary evidence suggests that selective serotonin reuptake inhibitors (SSRIs) are more effective in the presence of estrogen. Depression affects about 10% of pregnant women. Antidepressant medication should be considered during pregnancy if depression is moderate or severe, or if withdrawal of maintenance medication is likely to result in recurrent depression. The potential benefits of using antidepressant medications in a pregnant or breastfeeding woman should be balanced against the potential risks to the newborn. Because of the risk of neonatal withdrawal syndrome, SSRIs should be used at the lowest effective dose during the third trimester of pregnancy and should be tapered before delivery.
CONCLUSIONS: Continuing research is needed to determine how gender influences the risk, clinical presentation, and response to treatment of depression. Exploration of sex differences in animals and humans should aid in efforts to treat depression as an organic disorder rather than a psychological maladaptation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16860269     DOI: 10.1016/s1550-8579(06)80199-3

Source DB:  PubMed          Journal:  Gend Med        ISSN: 1550-8579


  48 in total

1.  Use of an operant paradigm for the study of antidepressant-induced sexual dysfunction.

Authors:  Lynda Uphouse; Jonathan Pinkston; Duane Baade; Christian Solano; Bless Onaiwu
Journal:  Behav Pharmacol       Date:  2015-10       Impact factor: 2.293

Review 2.  Sex differences modulating serotonergic polymorphisms implicated in the mechanistic pathways of risk for depression and related disorders.

Authors:  LeeAnn M Perry; Andrea N Goldstein-Piekarski; Leanne M Williams
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

3.  Gender-Related Hippocampal Proteomics Study from Young Rats After Chronic Unpredicted Mild Stress Exposure.

Authors:  Lin-Na Ning; Teng Zhang; Jiang Chu; Na Qu; Li Lin; Ying-Yan Fang; Yan Shi; Peng Zeng; Er-Li Cai; Xiao-Ming Wang; Qun Wang; You-Ming Lu; Xin-Wen Zhou; Qi Zhang; Qing Tian
Journal:  Mol Neurobiol       Date:  2017-01-07       Impact factor: 5.590

4.  Serotoninergic effects on judgments and social learning of trustworthiness.

Authors:  Arndis Simonsen; Jørgen Scheel-Krüger; Mads Jensen; Andreas Roepstorff; Arne Møller; Chris D Frith; Daniel Campbell-Meiklejohn
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

5.  Effects of long-term sertraline treatment and depression on coronary artery atherosclerosis in premenopausal female primates.

Authors:  Carol A Shively; Thomas C Register; Susan E Appt; Thomas B Clarkson
Journal:  Psychosom Med       Date:  2015-04       Impact factor: 4.312

6.  The effect of gender, age, and symptom severity in late-life depression on the risk of all-cause mortality: the Bambuí Cohort Study of Aging.

Authors:  Breno S Diniz; Charles F Reynolds; Meryl A Butters; Mary Amanda Dew; Josélia O A Firmo; Maria Fernanda Lima-Costa; Erico Castro-Costa
Journal:  Depress Anxiety       Date:  2013-12-18       Impact factor: 6.505

7.  Patients presenting with somatic complaints in general practice: depression, anxiety and somatoform disorders are frequent and associated with psychosocial stressors.

Authors:  Nader Haftgoli; Bernard Favrat; François Verdon; Paul Vaucher; Thomas Bischoff; Bernard Burnand; Lilli Herzig
Journal:  BMC Fam Pract       Date:  2010-09-15       Impact factor: 2.497

8.  Evidence from knockout mice that neuropeptide-Y Y2 and Y4 receptor signalling prevents long-term depression-like behaviour caused by immune challenge.

Authors:  Evelin Painsipp; Herbert Herzog; Peter Holzer
Journal:  J Psychopharmacol       Date:  2009-11-25       Impact factor: 4.153

9.  Delayed stress-induced differences in locomotor and depression-related behaviour in female neuropeptide-Y Y1 receptor knockout mice.

Authors:  E Painsipp; G Sperk; H Herzog; P Holzer
Journal:  J Psychopharmacol       Date:  2009-04-07       Impact factor: 4.153

Review 10.  Psychiatric epidemiology: challenges and opportunities.

Authors:  Ronald C Kessler
Journal:  Int Rev Psychiatry       Date:  2007-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.